Posted on

cbd oil dopamine

Cbd oil dopamine

Scientific studies are clear on this subject: short-term drug use increases the level of dopamine, but affects it drastically in the long term. This is why people who use cocaine, for example, always want more and cannot do without it to feel happy. The brain becomes dependent on these drugs to release dopamine, and a vicious cycle sets in.

CBD (cannabidiol), on the other hand, has no addictive effect on the brain. Even if the CBD molecule temporarily increases your dopamine level, it does not affect it in the long term. It doesn’t make you addicted or prevent your brain from producing dopamine without it. Although THC (tetrahydrocannabinol) is considered a psychoactive and unhealthy drug, it is also not considered addictive, unlike alcohol.

The problem is that certain substances, such as alcohol or hard drugs, can cause a sudden increase in this dopamine level for no reason. Even if you’re not doing anything in particular, you may feel a sense of well-being and mild satisfaction when you use them. At the time, it’s very pleasant. But in the long run, it reduces your ability to produce dopamine naturally, and causes you to use more to get that good feeling back. So what about CBD, this molecule that is neither psychoactive nor addictive? Does it act in the same way on the production of dopamine?

What are the effects of CBD in the long term?

As you can see, CBD does not have any harmful effects on the natural production of dopamine, even in the long term. What you need to remember is that most substances considered drugs slow down the production of cannabinoids, because your brain gets used to receiving them from an external source, without doing anything. Over the long term, the damage can be irreversible. But with hemp, studies have shown that after a certain period of time, the dopamine neurotransmitters return to normal. By comparing a group of former cannabis users with a group of non-users, researchers even found that there was no significant difference in their dopamine receptors.

Beyond its relationship with dopamine production, CBD acts in multiple ways on your brain. By acting on TRPV-1 receptors, it helps regulate body temperature, relieve inflammation and pain. Widely known for its positive action on chronic pain, CBD is also highly valued for its anti-epileptic and anti-anxiety properties. In fact, people suffering from epilepsy are increasingly using CBD to reduce the frequency and intensity of spasmodic disorders. In addition, CBD has antioxidant, analgesic, and neuroprotective properties that enhance its enormous therapeutic potential. The bottom line is that CBD is a natural substance that positively affects many receptors in our brain and body, and has yet to reveal the full extent of its powers.

CBD, a molecule with powerful therapeutic properties

The complexity of the brain is such that scientists are still divided on the issue of CBD and dopamine. One thing is for sure, the studies conducted so far have nevertheless highlighted the obvious link between CBD and the endocannabinoid system. In this way, CBD would act on many neurotransmitters, not just the happiness hormone in particular.

Even if its role in the process of dopamine production is still unclear, CBD acts on the production of this hormone, it is a fact. It’s hard to know how and why, but CBD does enhance dopamine production. Thus, it promotes the feeling of happiness, pleasure and satisfaction. With this conclusion, you may be wondering: What is the difference between CBD and drugs that increase dopamine production and make you addicted? Indeed, millions of people around the world consume CBD, often for therapeutic or medical purposes. And yet, they do not suffer from any form of CBD addiction. Why not? Simply because CBD does not act like a drug.

Cbd oil dopamine

In 2018, the U.S. Food and Drug Administration approved Epidiolex, a CBD concentrate, for two rare and severe forms of epilepsy, on the basis of several clinical trials.” (The New York Times, December 27, 2018). Research has shown that CBD may cause liver toxicity (Molecule, 2019; Healthline, August 20, 2019). More research on long-term safety and efficacy is required, especially for daily use of CBD.

Cannabidiol (CBD) is the talk of the town! Does CBD increase dopamine? Is it a “miracle cure?” The hottest supplement trend in years and the FDA hasn’t even approved it in food or dietary supplements. It was reported on June 12, 2019 in The New England Journal of Medicine that, “the FDA has taken the position that cannabidiol cannot be legally sold in supplements or food.” The hype for CBD as a “miracle cure” is unknown. We don’t know if cannabidiol can be a “miracle cure” for anything other than epilepsy at this time based on the scientific research! Cannabidiol is sold illegally online and in some retail stores in several dosage forms such as CBD Oil, CBD Candy and CBD Gummy Bears. Sales of CBD are projected to reach $22 billion by 2022.

Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the two most abundant cannabinoids found in the marijuana plant, with THC containing approximately 12% to 25% and CBD containing 1.4%. People who use THC regularly lower their dopamine levels. CBD is an adenosine activator and doesn’t include the psychoactive effects of THC. Like I said earlier, the latest scientific research has shown that CBD can inhibit dopamine release by inhibiting the TRPV1 receptor in the brain as well as increasing adenosine (Neuropharmacology, 2019, Drugs September 2019). The spice black pepper extract containing piperine has been shown to activate the TRPV1 receptor, and caffeine, which inhibits adenosine and enhances dopamine release. Increasing dopamine has been shown to increase energy, focus, memory, alertness, attention, confidence, mood, motivation, libido, weight control and creativity.

The mechanisms of action of CBD as a TRPV1 receptor inhibitor and adenosine reuptake inhibitor may lower dopamine levels in the brain. In my last article I talked about a new study about cannabis abuse and the connection between excessive cannabis use and decreased dopamine release in the brain, which could lead to impaired memory, attention and problem-solving abilities. A new study published in Molecular Psychiatry found evidence of a “compromised dopamine system” in heavy pot smokers, and significantly lower dopamine levels for those heavily dependent on cannabis. MRI and image studies have shown that drug abuses have marked decreases in dopamine release (Neuropharmacology, January 1, 2010).

As you can see, the hype on CBD is way ahead of the science! The scientific literature supports CBD for seizures and convulsions. CBD looks promising in the areas of reducing inflammation, relieving pain and anxiety, but much more research is needed. The mechanisms of action for CBD in the scientific literature are not fully understood until recently.

Cbd oil dopamine

Although dopamine D2 receptors are a main common target for antipsychotic drugs, it was essential, therefore, for this present study to examine whether cannabidiol had any direct action on dopamine D2 receptors that might account for the clinical antipsychotic effects observed by McGuire et al. 3 and Leweke et al. 2 Such an investigation was considered essential in order to test the basis for the commonly known dopamine hypothesis of psychosis, 5 especially as it is known that the potent cannabinoids HU210 and Win 55,212-2 cause behavioral dopamine supersensitivity and elevated D2High receptors. 5 That is, should there be no effect of cannabidiol on dopamine D2 receptors, despite having a clinical antipsychotic action, the dopamine hypothesis underlying psychosis would need to be modified.

Materials and Methods

Furthermore, in the presence of 200 μ m guanilylimidodiphosphate, the binding of [ 3 H]domperidone to the high-affinity site (at D2High receptors) was completely abolished. All the dopamine D2High receptors had converted to their D2Low state in the presence of the guanine nucleotide.

Cannabidiol/[ 3 H]domperidone competition

The competition between cannabidiol and [ 3 H]domperidone at brain dopamine D2 receptors was tested over a range of cannabidiol concentrations from 0.1 to 10,000 n m , using [ 3 H]domperidone concentrations (usually 2.3 n m ) that occupied about 82% of the D2 receptors. (On the basis of the fact that [ 3 H]domperidone had a Kd of about 0.5 n m for the D2 receptor, the fraction of D2 receptors occupied was C/(C+Kd) or 2.3 n m /(2.3 n m +0.5 n m )).